Day One Biopharmaceutical... (DAWN)
NASDAQ: DAWN
· Real-Time Price · USD
7.95
0.52 (7.00%)
At close: Oct 03, 2025, 3:59 PM
8.02
0.88%
After-hours: Oct 03, 2025, 05:42 PM EDT
7.00% (1D)
| Bid | 7.54 |
| Market Cap | 814.33M |
| Revenue (ttm) | 187.64M |
| Net Income (ttm) | -95M |
| EPS (ttm) | -0.89 |
| PE Ratio (ttm) | -8.93 |
| Forward PE | -9.53 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 8.51 |
| Volume | 3,194,173 |
| Avg. Volume (20D) | 1,612,385.1 |
| Open | 7.54 |
| Previous Close | 7.43 |
| Day's Range | 7.47 - 8.28 |
| 52-Week Range | 5.63 - 16.76 |
| Beta | -1.26 |
| Ex-Dividend Date | n/a |
About DAWN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DAWN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DAWN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsDay One Biopharmaceuticals Inc. is scheduled to release its earnings on
Oct 29, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-15.7%
Day One Biopharmaceuticals shares are trading lowe...
Unlock content with
Pro Subscription
2 months ago
+2.08%
Day One Biopharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 revenue results.
1 month ago · https://thefly.com
Day One Biopharmaceuticals initiated with an Overweight at Piper SandlerPiper Sandler initiated coverage of Day One Biopharmaceuticals with an Overweight rating and $25 price target. Piper thinks the stock move following the first two 2025 earnings reports is overdone and...
2 months ago · seekingalpha.com
Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call TranscriptDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Charles N. York - COO & CFO Jeremy Bender - CEO, President & Director Jo...
